Navigation Links
Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010
Date:8/2/2010

SAN FRANCISCO, Aug. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2010 financial results and provide a general business update on August 9, 2010, at 4:30 p.m. Eastern Time. A press release for the second quarter ended June 30, 2010 will be released after markets close on August 9, 2010.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a clinical development program that includes CONCERT, a Phase 3 trial assessing dimebon in patients with mild-to-moderate Alzheimer's disease, and HORIZON, a Phase 3 trial of dimebon in Huntington disease. In October 2009, Medivation entered into a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for both early- and late-stage prostate cancer. The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with castration-resistant prostate cancer who have previously been treated with docetaxel-based chemotherapy. Additional trials in earlier-stage prostate cancer will begin in 2010. For more information, please visit us at www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
2. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
3. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
4. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
5. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
6. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
7. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
10. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
11. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016  RxWiki Inc., a digital health company ... strategies of thousands of pharmacies through its Digital Pharmacist ... Inno,s "50 on Fire" Award in the Health ... to accept the award as one of Austin,s fastest ... Officer at RxWiki. "Our platform gives independent retail pharmacies ...
(Date:12/9/2016)... SAN DIEGO , Dec. 9, 2016 /PRNewswire/ ... with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ... program targeting ,LpxC, for the treatment of bacterial ... LpxC has been recognized as an attractive antibacterial ... however, a lack of suitable chemical starting points ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... Patient warming ... of blood during surgeries, lowering the risks of neurological disorders ... of SSIs. The patient warming systems can be segmented into ... benefits in turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology:
(Date:12/9/2016)... , ... December 09, 2016 , ... ... through the Pennsylvania Cable Network (PCN) during the summer of 2016. The program ... Grant provided by the United States Department of Health and Human Services Administration. ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that due ... Texas, they are expanding their presence in Dallas. One of the most exciting parts ... new jobs to the Dallas and Forth Worth market. STAT takes pride in treating ...
Breaking Medicine News(10 mins):